AETHLON MEDICAL, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
AETHLON MEDICAL, INC. (AEMD) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $427.12 thousand for the 9-month period ending 2022-12-31, per its 10-Q filed 2023-02-13.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-02-13
- AETHLON MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-06-30 was -$2.15M, a 114.05% decline year-over-year.
- AETHLON MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-06-30 was $15.31M.
- AETHLON MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $7.25M, a 2289.17% increase from fiscal 2021.
- AETHLON MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $303.52K, a 94.75% decline from fiscal 2020.
- AETHLON MEDICAL, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was $5.78M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-12-31 | $427.12K 10-Q · filed 2023-02-13 | |||
| 2022-09-30 | $2.53M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$2.15M 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $7.25M 10-K · filed 2022-06-28 | |||
| 2021-12-31 | $10.57M 10-Q · filed 2023-02-13 | |||
| 2021-09-30 | $13.36M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $15.31M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $303.52K 10-K · filed 2022-06-28 | |||
| 2020-03-31 | $5.78M 10-K · filed 2021-06-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |